Skip to main content

Aminolaevulinic acid diffusion characteristics in ‘in vitro’ normal human skin and actinic keratosis: implications for topical photodynamic therapy

Buy Article:

$51.00 plus tax (Refund Policy)



The response rate of aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) in certain subtypes of actinic keratosis (AK), such as hypertrophic and hyperkeratotic lesions, is variable, an effect attributable to a supposed lack of ALA penetration. A detailed and depth-related profile of spatial ALA permeation in AK following drug administration would lead to a greater understanding of concentrations achievable before protoporphyrin IX biosynthesis and subsequent PDT. Methods:

ALA penetration through excised normal human skin (NS) and AK lesions was evaluated using a cryostatic sectioning technique and radio-isotope counting following drug delivery using a novel, bioadhesive patch, loaded with 19, 38 or 50 mg/cm2 ALA. Results:

Distinct differences in ALA concentration with respect to depth between AK and NS samples were shown, particularly within the superficial layers of the tissue structure, down to a depth of 1.0 mm. Patch application times were shown to influence ALA concentrations in tissue, but there was no clear correlation between ALA penetration in AK lesions taken from different body locations and from patients of different age. Similarly, the thickness of stratum corneum was not related to the ALA distribution profiles. Conclusions:

Sizable variation in ALA concentration was a prominent feature of profiles through AK lesions, which may explain the variation of observed protoporphyrin IX production seen in the clinical implementation of AK PDT. That said, the results of this study show sufficient ALA penetration to a depth of 1.0 mm, which should be satisfactory for successful treatment of the majority of non-hyperkeratotic, hypertrophic AK using patch-based delivery methods.

Keywords: actinic keratosis; aminolaevulinic acid; normal skin

Document Type: Research Article


Affiliations: 1: School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, UK, 2: Department of Pathology, The Royal Hospitals, Belfast, UK, 3: Department of Dermatology, The Royal Hospitals, Belfast, UK, 4: Department of Electronic Engineering, National University of Ireland Maynooth, Maynooth, Co. Kildare, Ireland, and 5: Department of Dermatology, Belfast City Hospital, Belfast, UK

Publication date: August 1, 2008


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more